Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PALLADONE vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Management of moderate to severe pain requiring daily opioid treatment
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Hepatic via CYP3A4 and CYP2D6 to active metabolite hydromorphone; also via glucuronidation.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 95-99% bound to albumin and alpha-1-acid glycoprotein.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Vd ~4 L/kg (range 2-6 L/kg). Large Vd indicates extensive tissue distribution.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: ~40% (range 20-60%) due to first-pass metabolism; rectal: similar to oral.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For Cr Cl 30-59 m L/min: start with 50% of recommended dose and titrate cautiously; for Cr Cl <30 m L/min: not recommended.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: start at 50% of usual dose and monitor; Child-Pugh Class C: not recommended.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Weight-based dosing: 0.1-0.2 mg/kg orally every 4-6 hours as needed (immediate-release); maximum single dose 5 mg. Extended-release not recommended in children.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Start at the low end of dosing range (e.g., 2-4 mg immediate-release every 4-6 hours) and titrate slowly; monitor for increased sensitivity and respiratory depression.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interaction with alcohol and CNS depressants.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Respiratory depression,Addiction and abuse potential,Risks from concomitant use of benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome,Adrenal insufficiency,Severe hypotension,Seizures,Serotonin syndrome with serotonergic drugs
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Hypersensitivity to hydromorphone or any component,Concurrent use of MAOIs or within 14 days
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid grapefruit juice as it may increase hydromorphone levels. Avoid alcohol in any form (including beverages, cooking wines, and medications containing alcohol) due to risk of additive CNS depression and respiratory depression. High-fat meals may delay absorption; take consistently with or without food to maintain stable effects.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural tube defects, based on some epidemiologic studies; however, absolute risk is low. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Additionally, use near term may cause neonatal respiratory depression, and use during labor may prolong labor.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.65. The estimated infant dose via breast milk is about 0.5-1% of the maternal weight-adjusted dose. While generally considered compatible with breastfeeding at low maternal doses, caution is advised; monitor infant for excessive drowsiness, respiratory depression, and feeding difficulties. Avoid use in mothers with high-dose or prolonged therapy.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Pregnancy may alter pharmacokinetics of hydromorphone: increased clearance and volume of distribution may reduce serum concentrations. Dose adjustments may be necessary to maintain analgesic efficacy. Close monitoring for breakthrough pain and signs of withdrawal is recommended. Due to lack of robust data, titrate dose based on clinical response and maternal safety, using the lowest effective dose. Avoid abrupt discontinuation to prevent withdrawal.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
PALLADONE (hydromorphone extended-release) is a potent mu-opioid agonist. Do not crush or allow patients to chew capsules; this can cause rapid release and fatal overdose. Use with extreme caution in patients with respiratory compromise, COPD, or sleep apnea. Initiate at the lowest effective dose and titrate slowly. Monitor for constipation and prescribe a bowel regimen prophylactically. Consider naloxone co-prescription for high-risk patients. Avoid use in patients with paralytic ileus or suspected GI obstruction. Renal impairment requires dose adjustment due to accumulation of hydromorphone-3-glucuronide.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow capsules whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any medications containing alcohol while taking this drug as it increases risk of dangerous side effects.,Do not drive or operate heavy machinery until you know how PALLADONE affects you; it may cause dizziness or drowsiness.,This medication carries a risk of addiction, abuse, and misuse; store it securely out of reach of others.,Report any difficulty breathing, extreme drowsiness, confusion, or signs of allergic reaction immediately.,Do not stop suddenly; your doctor will help you taper off to prevent withdrawal symptoms.,Constipation is common; increase fluid and fiber intake and use laxatives as recommended by your doctor.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PALLADONE vs ALFENTANIL, answered by our medical review team.
PALLADONE is a Opioid Analgesic that works by Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PALLADONE and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PALLADONE is: Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PALLADONE and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PALLADONE is classified as Category C. PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.